Harvard Bioscience Accelerates Growth with Human-Relevant Translational Tools, Leading Recurring Revenue and Innovation in Preclinical Research (May 2026) 10121415
Harvard Bioscience, Inc. (NASDAQ: HBIO) Announces Strategic ...
Sign in to continue:
Harvard Bioscience, Inc. (NASDAQ: HBIO) Announces Strategic ...
Sinostar PEC Holdings Limited 1Q26 Financial Results Analysi...
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-...
Ambiq Micro, Inc. Delivers Robust Q1 2026 Results and Accele...
Under Armour Reports Fiscal 2026 Q4 and Full-Year Results; A...
Mereo BioPharma Q1 2026 Financial Results & Corporate Update...
Xilio Therapeutics Q1 2026 Financial Results: Detailed Inves...
Sagimet Biosciences Q1 2026 Financial Results & Corporate Up...
Fuji Offset Plates Manufacturing Ltd 2026 AGM: Key Outcomes ...
Antero Midstream Corporation Files Form 8-K: Key Takeaways f...